Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting
May 23 2017 - 6:30AM
Vical Incorporated (Nasdaq:VICL) announced today that the company
will present clinical data on its completed Phase 1 trial of its
novel antifungal, VL-2397, at the American Society of Microbiology
(ASM) Microbe 2017 meeting, taking place June 1 – 5 in New Orleans.
The Company will also present data from non-clinical VL-2397
studies. VL-2397 will be featured in an oral presentation and four
poster presentations at the conference. Abstracts are available
through the ASM Microbe Online Program Planner.
Oral Presentation
- Sean Sullivan, Ph.D., Vical’s Senior Executive Director,
Pharmaceutical Sciences, will present “Development of VL-2397 as a
Novel Antifungal Drug Candidate to Treat Invasive Aspergillosis” in
the conference’s New Agents Discovery Summary Session: Early New
Antimicrobial Agents on June 3rd at 10:25 am. The slides presented
by Dr. Sullivan will be made available on Vical’s website following
the presentation.
Poster Presentations
- Mammen P. "Anza" Mammen, Jr., M.D., Vical’s Vice President,
Clinical Vaccines, will present the poster, “Phase 1 Safety and
Pharmacokinetics Study of VL-2397, a Novel Antifungal Agent,” on
the safety and pharmacokinetics data from the VL-2397 Phase 1
study. This poster session begins on June 2nd at 12:45pm.
- Laura Kovanda from Astellas Pharma and the University of
Liverpool, will present the poster, “Population Pharmacokinetic
Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of
a Single and Multiple Dose Phase 1 Study,” on a population
pharmacokinetic analysis from the VL-2397 Phase 1 study. This
poster session begins on June 2nd at 12:45pm.
- Dr. Sean Sullivan will present the poster, “Characterization of
Potential Drug Interactions and Off-Target Activities of VL-2397, a
Novel Antifungal Agent against Invasive Aspergillosis,” on the
limited potential drug interactions of VL-2397 demonstrated in
vitro. This poster session begins on June 3rd at 12:15pm.
- Nathan Wiederhold, Pharm.D., from the University of Texas
Health Science Center San Antonio, will present the poster, “The
Novel Antifungal VL-2397 Demonstrates Efficacy in an In
Vivo Model of Invasive Candidiasis Caused by Wild-Type and
Multi-Drug Resistant Candida glabrata,” reviewing an NIH-sponsored
in vivo study that investigated the effect of VL‑2397 to treat
wild-type and drug-resistant Candida glabrata. This poster session
begins on June 3rd at 12:15pm.
Vical plans to conduct a Phase 2 efficacy study
to evaluate VL-2397 for the treatment of invasive aspergillosis and
is working with clinical experts and the FDA towards this
objective. The FDA has granted Vical Qualified Infectious Disease
Product (QIDP), Orphan Drug and Fast Track designations to VL-2397
for the treatment of invasive aspergillosis. Under the QIDP
designation Vical has been able to interact intensively with the
FDA on the design of the Phase 2 trial and in exploring an
expedited development pathway for VL‑2397.
About VicalVical develops
biopharmaceutical products for the prevention and treatment of
chronic or life-threatening infectious diseases, based on its
patented DNA delivery technologies and other therapeutic
approaches. Additional information on Vical is available at
www.vical.com.
Forward-Looking StatementsThis
press release contains forward-looking statements subject to risks
and uncertainties that could cause actual results to differ
materially from those projected. Forward-looking statements include
anticipated developments in clinical programs, including the plans,
timing of initiation, and enrollment for clinical trials. Risks and
uncertainties include whether Vical or others will continue
development of VL-2397; whether Vical will be able to obtain
regulatory allowances or guidance necessary to proceed with
proposed clinical trials or implement anticipated clinical trial
designs; whether on-going or planned clinical trials will be
initiated or completed on the timelines Vical currently expects,
whether any product candidates will be shown to be safe and
efficacious in clinical trials; whether Vical will have access to
sufficient capital to fund its planned development activities;
whether Vical will seek or gain approval to market any product
candidates; and additional risks set forth in the Company's filings
with the Securities and Exchange Commission. These forward-looking
statements represent the Company's judgment as of the date of this
release. The Company disclaims, however, any intent or obligation
to update these forward-looking statements.
Contact:
Andrew Hopkins
(858) 646-1127
Website: www.vical.com
Vical (NASDAQ:VICL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vical (NASDAQ:VICL)
Historical Stock Chart
From Sep 2023 to Sep 2024